直接抗病毒药物治疗是否影响丙型肝炎肝硬化患者肝细胞癌的早期复发?一项前瞻性多中心研究
该前瞻性多中心研究纳入143例经治愈性治疗后完全缓解、随后接受直接抗病毒药物(DAA)治疗的丙型肝炎肝硬化患者,通过RESIST-HCV数据库监测。96%患者获得持续病毒学应答,6、12、18个月肝细胞癌复发率分别为12%、26.6%、29.1%,主要肿瘤大小和既往肝细胞癌复发史为独立危险因素。
要点
- DAA治疗后丙型肝炎肝硬化患者肝细胞癌早期复发概率仍高,6、12、18个月复发率分别为12%、26.6%、29.1%。
- 既往肝细胞癌复发史和主要肿瘤大小是肝细胞癌复发的独立危险因素。
- 复发风险与文献中未接受DAA治疗的患者相当,但并未更高。
核心结论
- 既往治愈的肝细胞癌患者在接受DAA根除丙型肝炎后,肝细胞癌早期复发概率仍然很高。
- 该风险与文献中未接受DAA治疗的患者相当,但并未更高。
- 既往肝细胞癌复发史和肿瘤大小可用于对肝细胞癌早期复发风险进行分层。
- 需要进一步研究评估DAA对晚期复发和死亡率的影响。
研究设计与样本
- 前瞻性多中心研究,纳入143例经治愈性治疗后完全缓解、随后接受DAA治疗的丙型肝炎肝硬化患者,通过基于网络的RESIST-HCV数据库监测。
- 收集临床、生物学和病毒学数据,主要终点为从DAA开始计算的肝细胞癌早期复发概率,采用Kaplan-Meier法分析。
主要发现
- 86%的患者为Child-Pugh A级,76%的患者为BCLC A期。
- 96%的患者获得持续病毒学应答。
- 观察到24例肝细胞癌复发,结节型占83%,浸润型占17%。
- 6、12、18个月肝细胞癌复发率分别为12%、26.6%、29.1%。
- Cox多因素模型显示,主要肿瘤大小和既往肝细胞癌复发史是肝细胞癌复发的独立危险因素。
关键数值与推荐
- 6个月肝细胞癌复发率为12%。
- 12个月肝细胞癌复发率为26.6%。
- 18个月肝细胞癌复发率为29.1%。
- 24例复发中结节型占83%,浸润型占17%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要进一步研究评估DAA对晚期复发和死亡率的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Data on HCV-related hepatocellular carcinoma (HCC) early recurrence in patients whose HCC was previously cured, and subsequently treated by direct-acting antivirals (DAAs), are equivocal. AIM: To assess the risk of HCC early recurrence after DAAs exposure in a large prospective cohort of HCV-cirrhotic patients with previous successfully treated HCC, also looking for risk factors for cancer early recurrence. METHODS: We enrolled 143 consecutive patients with complete response after curative treatment of HCC, subsequently treated with DAAs and monitored by the web-based RESIST-HCV database. Clinical, biological, and virological data were collected. The primary endpoint was the probability of HCC early recurrence from DAA starting by Kaplan-Meier method. RESULTS: Eighty-six per cent of patients were in Child-Pugh class A and 76% of patients were BCLC A. Almost all patients (96%) achieved sustained virological response. Twenty-four HCC recurrences were observed, with nodular or infiltrative pattern in 83% and 17% of patients, respectively. The 6-, 12- and 18-month HCC recurrence rates were 12%, 26.6% and 29.1%, respectively. Main tumour size and history of prior HCC recurrence were independent risk factors for HCC recurrence by Cox multivariate model. CONCLUSIONS: Probability of HCC early recurrence in patients who had HCC previously cured remains high, despite HCV eradication by DAAs. Risk was comparable but not higher to that reported in literature in DAA-untreated patients. Previous HCC recurrence and tumour size can be used to stratify the risk of HCC early recurrence. Further studies are needed to assess impact of DAAs on late recurrence and mortality.
引用
- Cabibbo G, Petta S, Calvaruso V, et al. Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study. Aliment Pharmacol Ther. 2017. PMID: 28791711. doi:10.1111/apt.14256
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。